远程医疗公司Hims & Hers Health Inc.（股票代码：HIMS）今日盘中出现逆势大涨，截至发稿时股价上涨5.08%。这一涨势引起了市场的广泛关注，尤其是在公司刚刚失去与诺和诺德的重要合作的背景下。
据报道，丹麦制药巨头诺和诺德（NVO）近日终止了与Hims & Hers Health的合作协议，该协议此前允许Hims & Hers直接销售诺和诺德的明星减肥药Wegovy。诺和诺德表示，尽管Wegovy的供应短缺问题已得到缓解，但Hims & Hers去年推出的低价复合版本仍未符合联邦相关法规。这一决定引发了Hims & Hers首席执行官Andrew Dudum的强烈抗议。
尽管失去了这个重要的合作伙伴，Hims & Hers的股价却出现了反弹。分析人士认为，这可能是因为市场认为公司有能力独立发展其业务模式，或者投资者预期公司可能会寻求新的合作伙伴。此外，也有可能是部分投资者认为此前的跌幅已经过度，导致当前股价被低估。无论如何，这一意外的股价走势表明，投资者对Hims & Hers的长期前景仍保持乐观态度。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.